Oxford University's latest spin-out is the drug-discovery company InhibOx Ltd, which uses advanced computational methods to carry out in silico screening on a massive scale to discover new leads for drugs quickly and cost-effectively. Initial projects are focused on cancer research, though other indications will be added in due course.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Oxford University's latest spin-out company is the drug delivery and glycoprotein specialist Glycoform Ltd, which uses expertise in identifying novel carbohydrate - cell surface receptor- binding properties to develop unique drug targeting systems.
Oxford Risk Research and Analysis (ORRA), a new spin-out company founded by Oxford University zoologists, has been created to provide services to businesses who are making decisions related to risks. Intriguingly, among the useful insights into risk management are those gained from studies on animal behaviour.
A revolutionary new test for identifying people infected with tuberculosis (TB), one of the leading causes of death worldwide, will shortly be launched by Oxford Immunotec Ltd, a new spin-out company from the University of Oxford. The test radically improves the speed and accuracy with which the disease can be identified. It has been developed to replace the existing skin test for TB, which is given to 600,000 UK schoolchildren every year.
Technology merger offers advantages for next generation flat panel displays and lighting applications.
KS Biomedix, a biopharmaceutical company based in Guildford (Surrey, UK) has licensed in a novel protein engineering technology from Oxford University Innovation, the technology transfer company of Oxford University, UK.